Ftse Mib
34.249,77
0,91%
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
NASDAQ Composite
15.927,90
2,03%
Bitcoin
63.575,01
0,26%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistenza
Home Investire Azioni U.S.A. NASDAQ BiondVax Pharmaceuticals Ltd (BVXV) BiondVax Pharmaceuticals Ltd (BVXV) Notizie

BiondVax Pharmaceuticals Ltd

BVXV
1,36
0,00 (0,00%)
26 Apr 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
16/4/202423:27EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/4/202413:00PRNUSScinai to showcase its novel biological local therapeutic..
12/3/202421:17EDGAR2Form SC 13D - General statement of acquisition of beneficial..
12/3/202413:00PRNUSScinai leadership to attend BIO-Europe Spring 2024
13/2/202413:00PRNUSScinai Welcomes Liat Halpert as Head of Business Development..
04/1/202422:01PRNUSScinai Immunotherapeutics Announces Closing of Exercise of..
20/11/202313:30PRNUSScinai Immunotherapeutics Regains Compliance with Nasdaq's..
07/9/202323:27EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
06/9/202318:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/9/202317:44EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/9/202312:00GLOBEBiondVax Pharmaceuticals Ltd. Rebrands as Scinai..
28/8/202322:01EDGAR2Form 424B2 - Prospectus [Rule 424(b)(2)]
28/8/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
24/8/202322:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/8/202312:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/8/202322:16EDGAR2Form F-3 - Registration statement by foreign private issuers
18/8/202316:07EDGAR2Form 6-K/A - Report of foreign issuer [Rules 13a-16 and..
14/8/202312:08EDGAR2Form 6-K/A - Report of foreign issuer [Rules 13a-16 and..
11/8/202315:44EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/8/202315:00GLOBEBiondVax Reports Second Quarter Financial Results and..
01/8/202322:01GLOBENasdaq Grants BiondVax Extension to Regain Compliance with..
01/8/202322:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/7/202321:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/7/202314:17GLOBEIBN Announces Latest Episode of The Bell2Bell Podcast..
05/7/202315:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/7/202322:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/7/202322:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/6/202313:00GLOBEBiondVax signs exclusive license agreement for development..
Apertura: Min: Max:
Chiusura: 1,36

La tua Cronologia

NASDAQ
BVXV
BiondVax Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network